Twist Bioscience (TWST) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports ...

Cathie Wood's ARK sold $2.78M Twist Bioscience, bought Tempus AI & WeRide Jan 26. Full breakdown of ARK Invest's latest AI ...

On the buying side, ARK continues to show interest in the artificial intelligence space. The fund acquired 7,737 shares of Tempus AI Inc (NASDAQ:TEM) across its ARKK and ARKG ETFs, totaling $505,380.

Ongoing combination of Twist NGS library preparation kits with firefly will continue to expand SPT Labtech’s portfolio of ...

-- Launch of End-to-End Workflow for AVITI and AVITI24™ Enabling Sample to Sequencer in as Little as Five Hours -- -- Twist Gains Exclusive Access to the new, co-developed Trinity Freestyle™ ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, ...

Twist Bioscience (NASDAQ:TWST) is gearing up to announce its quarterly earnings on Monday, 2025-05-05. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Twist Bioscience specializes in synthetic DNA production, providing gene fragments, next generation sequencing (NGS) tools, and antibody discovery platforms to research, diagnostic, pharmaceutical, ...

Shares of Twist Bioscience climbed after the company said it expects to post first-quarter revenue ahead of its previous guidance. The stock rose 8.1%, to $38.19, late Monday morning, but has fallen ...